drug
alirocumab
Marketedupdated 3mo agoby Sanofi-Aventis US LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Antibody drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 6 investigational indications.
indications
investigational
Hyperlipidemia
all catalysts(14)
approval · 14
Jul 24, 2015
approval
$REGN803.48-0.31%
PRALUENT (ALIROCUMAB) — FDA approval
alirocumab
→
Apr 24, 2017
approval
$REGN803.48-0.31%
PRALUENT (ALIROCUMAB) — FDA approval
alirocumab
→
Jul 27, 2017
approval
$REGN803.48-0.31%
PRALUENT (ALIROCUMAB) — FDA approval
alirocumab
→
Sep 20, 2017
approval
$REGN803.48-0.31%
PRALUENT (ALIROCUMAB) — FDA approval
alirocumab
→
Jul 20, 2018
approval
$REGN803.48-0.31%
PRALUENT (ALIROCUMAB) — FDA approval
alirocumab
→
Aug 22, 2018
approval
$REGN803.48-0.31%
PRALUENT (ALIROCUMAB) — FDA approval
alirocumab
→
Nov 6, 2018
approval
$REGN803.48-0.31%
PRALUENT (ALIROCUMAB) — FDA approval
alirocumab
→
Apr 26, 2019
approval
$REGN803.48-0.31%
PRALUENT (ALIROCUMAB) — FDA approval
alirocumab
→
Apr 26, 2019
approval
$REGN803.48-0.31%
PRALUENT (ALIROCUMAB) — FDA approval
alirocumab
→
Mar 10, 2020
approval
$REGN803.48-0.31%
PRALUENT (ALIROCUMAB) — FDA approval
alirocumab
→
Apr 1, 2021
approval
$REGN803.48-0.31%
PRALUENT (ALIROCUMAB) — FDA approval
alirocumab
→
Apr 1, 2021
approval
$REGN803.48-0.31%
PRALUENT (ALIROCUMAB) — FDA approval
alirocumab
→
Mar 8, 2024
approval
$REGN803.48-0.31%
PRALUENT (ALIROCUMAB) — FDA approval
alirocumab
→
Oct 9, 2025
approval
$REGN803.48-0.31%
PRALUENT (ALIROCUMAB) — FDA approval
alirocumab
→
Trials studying alirocumab
- phase2A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
- —Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD)
- phase2PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung
- phase2TOP 2301: Neoadjuvant Chemo for NSCLC
- —Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
- phase1Alirocumab in Patients with Sepsis
- —Retrospective Analysis of the Effect of In-hospital Initiation of PCSK9i on Clinical Outcomes in Chinese ACS Patients
News(5)
- Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitorMerck’s once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options.biospace · 29d ago
- Gene editing developer Scribe plots an IPOThe California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to go public in 2026.biopharma_dive · 1mo ago
- Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelicsLilly shares dipped, and Novo’s climbed, as Foundayo’s early trajectory diverged from that of oral Wegovy. Elsewhere, Regeneron inked a drug price deal and two companies announced leadership changes.biopharma_dive · 3mo ago
- STAT+: Pharmalittle: We’re reading about a Trump deal with Regeneron, reclassifying medical marijuana, and morePresident Trump heralded a drug-pricing agreement with Regeneron, closing the last of 17 deals sought by the White Housestat · 3mo ago
- STAT+: Trump celebrates closing first round of drug pricing deals, promises more aheadA deal with Regeneron was the last of 17 initially sought by the White House.stat · 3mo ago
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that